Walker Neal's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Apr 25, 2022
- Accession no.
- 0001209191-22-025537
- Filed
- Apr 25, 2022
- Trade date
- Apr 21-25, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.06M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Walker NealCIK 0001604457 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | SSaleDisposed | −25,000 | $15.24 | −$381,000 | 1,290,763 | Direct | |
| Apr 22, 2022 | Common Stock | SSaleDisposed | −25,000 | $15.04 | −$376,000 | 1,265,763 | Direct | |
| Apr 25, 2022 | Common Stock | SSaleDisposed | −20,000 | $15.18 | −$303,600 | 1,245,763 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.